A comprehensive review of immune checkpoint inhibitor-related diabetes mellitus: incidence, clinical features, management, and prognosis.

Front Immunol · 2024 · PMC11570264 · PMID 39559363

Europe PMC DOI

hedged sentence

0.2460

closest p · 4.9× alpha

0.2460

boldest claim

The sentences

did not reach statistical significanceP =0.246not close (p > 0.1)

A trend for increased incidence of ICI-DM (0.44%, 11/2518) with dual ICI combination consisting of durvalumab and tremelimumab, an anti-CTLA4 antibody, did not reach statistical significance compared with durvalumab monotherapy ( P =0.246).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.